Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics develops small molecule drugs for lung fibrosis, chronic pain, depression and multiple sclerosis. It last closed at $9.55 on Nov 17, down 1.24% on the day. The average 12-month price target from 3 analysts is $20.33 (+112.9% from the last close), with a high of $30.00 and a low of $14.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CTNM, 100% of them bullish and 0% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From CTNM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on CTNM in the past 90 days. The average target is $20.33, with a high of $30.00 and a low of $14.00, compared with the last close of $9.55.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 15 | Jones Trading | Target raised | Buy | $24 → $30 |
| Oct 14 | Baird | Downgrade | Hold | $19 → $14 |
| Sep 28 | Morgan Stanley | Maintained | Hold | $17 |
| Sep 15 | Jones Trading | Maintained | Buy | $24 |
| Sep 15 | Baird | Maintained | Buy | $19 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 40% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the Pivot at $9.52, and the nearest resistance the Pivot R1 at $9.71.
| RSI (14) | 45.83 | Middle of its range | Neutral |
| MACD | -0.22 | Above its signal line | Bullish |
| Stochastic | 50.6 | Middle of its range | Neutral |
| ADX (14) | 21.4 | Weak trend | |
| Williams %R | -58.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 16.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −1.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.83 | Typical daily range, 8.7% of price |
| RSI (14) | 40.30 | Middle of its range | Neutral |
| MACD | -1.16 | Below its signal line | Bearish |
| Stochastic | 26.3 | Middle of its range | Neutral |
| ADX (14) | 25.6 | Trending down | |
| Williams %R | -74.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -93.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −35.6% | Change over 10 sessions | Bearish |
| ATR (14) | $2.17 | Typical daily range, 22.7% of price |
What happened before
See how CTNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in CTNM in the last 90 days.
CTNM Institutional Ownership
Full report →- ▲71 buying vs 38 selling
- ▲Held by funds +16.6 pts
- ▲Funds holding +17
- ▼Superinvestors: 0 added, 4 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 119 | 102 | +16.7% |
| In funds' top 10 | 4 | 4 | 0.0% |
| Held by funds | 148.9% | 132.3% | +16.6 pts |
| New / increased | 28 / 43 | 28 / 32 | +18.3% |
| Reduced / sold out | 27 / 11 | 19 / 15 | +11.8% |
| Put/call ratio | 0.25 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTNM is in one of them and how their past CTNM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CTNM in an article yet. Here's the latest on the wider market.
About Contineum Therapeutics
Contineum Therapeutics is a San Diego, California company developing small molecule drugs for neuroscience and immunology conditions. Its lead candidate, PIPE-791, is being developed as a pill taken once a day for idiopathic pulmonary fibrosis and is also being studied for chronic pain. A second candidate, PIPE-307, is being developed for depression and multiple sclerosis in partnership with Johnson & Johnson. The company's drugs are intended for patients with these conditions, and none are approved for sale yet.
- Headquarters
- San Diego, CA



